[{"id":"0340b14e-a127-4e74-868c-fbd3285909ff","acronym":"","url":"https://clinicaltrials.gov/study/NCT05761951","created_at":"2023-03-09T15:01:38.080Z","updated_at":"2025-02-25T16:18:37.564Z","phase":"Phase 2","brief_title":"Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer","source_id_and_acronym":"NCT05761951","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CTNNB1 • AXIN1 • RSPO2 • ZNRF3","pipe":" | ","alterations":" CTNNB1 mutation","tags":["CTNNB1 • AXIN1 • RSPO2 • ZNRF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTNNB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • sirexatamab (DKN-01)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 08/29/2023","start_date":" 08/29/2023","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2029","study_completion_date":" 01/31/2029","last_update_posted":"2024-11-18"},{"id":"a18b55f5-28ba-44e3-9d03-4d9885a2070f","acronym":"DisTinGuish","url":"https://clinicaltrials.gov/study/NCT04363801","created_at":"2021-01-18T21:05:30.406Z","updated_at":"2024-07-02T16:35:22.721Z","phase":"Phase 2","brief_title":"A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","source_id_and_acronym":"NCT04363801 - DisTinGuish","lead_sponsor":"Leap Therapeutics, Inc.","biomarkers":" PD-L1 • DKK1","pipe":"","alterations":" ","tags":["PD-L1 • DKK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • leucovorin calcium • sirexatamab (DKN-01)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 232","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-01-22"},{"id":"df5e233b-03dd-4775-95b8-d495623e5e0e","acronym":"KEYNOTE-731","url":"https://clinicaltrials.gov/study/NCT02013154","created_at":"2021-01-17T17:36:08.241Z","updated_at":"2025-02-25T16:13:38.130Z","phase":"Phase 1","brief_title":"A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab","source_id_and_acronym":"NCT02013154 - KEYNOTE-731","lead_sponsor":"Leap Therapeutics, Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • paclitaxel • sirexatamab (DKN-01)"],"overall_status":"Completed","enrollment":" Enrollment 151","initiation":"Initiation: 05/05/2014","start_date":" 05/05/2014","primary_txt":" Primary completion: 07/19/2019","primary_completion_date":" 07/19/2019","study_txt":" Completion: 01/11/2021","study_completion_date":" 01/11/2021","last_update_posted":"2023-11-01"},{"id":"98f9903f-5399-470c-a4e4-810aaee0f5a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04681248","created_at":"2022-08-29T14:58:12.640Z","updated_at":"2024-07-02T16:35:35.195Z","phase":"","brief_title":"Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT04681248","lead_sponsor":"Leap Therapeutics, Inc.","biomarkers":" RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3","pipe":"","alterations":" ","tags":["RNF43 • CTNNB1 • AXIN1 • RSPO2 • RSPO3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirexatamab (DKN-01)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2023-09-29"},{"id":"09a7fca4-960e-494c-b5fa-f25c8e15bcf8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03645980","created_at":"2021-01-18T17:53:52.165Z","updated_at":"2024-07-02T16:36:39.770Z","phase":"Phase 1/2","brief_title":"DKN-01 Inhibition in Advanced Liver Cancer","source_id_and_acronym":"NCT03645980","lead_sponsor":"Johannes Gutenberg University Mainz","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sorafenib • sirexatamab (DKN-01)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 10/10/2018","start_date":" 10/10/2018","primary_txt":" Primary completion: 08/31/2021","primary_completion_date":" 08/31/2021","study_txt":" Completion: 08/31/2022","study_completion_date":" 08/31/2022","last_update_posted":"2020-10-22"},{"id":"188dcc9e-c0b4-491c-8518-9abf60b1cb6e","acronym":"EORTC 1741-GITCG","url":"https://clinicaltrials.gov/study/NCT03818997","created_at":"2021-01-18T18:52:06.013Z","updated_at":"2024-07-02T16:36:50.596Z","phase":"Phase 2","brief_title":"Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer","source_id_and_acronym":"NCT03818997 - EORTC 1741-GITCG","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • paclitaxel • sirexatamab (DKN-01)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2019","start_date":" 12/01/2019","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 04/01/2022","study_completion_date":" 04/01/2022","last_update_posted":"2020-02-05"},{"id":"bea13253-9f6e-480f-bdfd-00d0fcb42ee4","acronym":"1741-GITCG","url":"https://clinicaltrials.gov/study/NCT03760289","created_at":"2021-01-18T18:28:51.619Z","updated_at":"2025-02-25T18:19:55.080Z","phase":"Phase 2","brief_title":"DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer","source_id_and_acronym":"NCT03760289 - 1741-GITCG","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Tecentriq (atezolizumab) • paclitaxel • sirexatamab (DKN-01)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 123","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 04/01/2021","primary_completion_date":" 04/01/2021","study_txt":" Completion: 04/01/2022","study_completion_date":" 04/01/2022","last_update_posted":"2018-11-30"},{"id":"3ba2c543-7e43-449a-9147-229183bef6af","acronym":"","url":"https://clinicaltrials.gov/study/NCT03756532","created_at":"2021-01-18T18:27:59.801Z","updated_at":"2025-02-26T11:19:08.718Z","phase":"Phase 1b/2a","brief_title":"A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1","source_id_and_acronym":"NCT03756532","lead_sponsor":"New York University School of Medicine","biomarkers":" DKK1","pipe":"","alterations":" ","tags":["DKK1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • sirexatamab (DKN-01)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 97","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 03/01/2022","study_completion_date":" 03/01/2022","last_update_posted":"2018-11-28"}]